A Qatar-based study involving 121,700 patients has underscored the importance of the post-vaccination monitoring to optimise ...

The selection of a first-line treatment for patients with advanced EGFR -positive non-small cell lung cancer (NSCLC) has ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently dominated by AstraZeneca's Tagrisso (osimertinib) but currently being shaken up ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...